The potential contribution of aromatase inhibitors to frailty in breast cancer patients with cardiovascular events

The potential contribution of aromatase inhibitors to frailty in breast cancer patients with cardiovascular events

Bibliographic Details
Main Authors:	Yu Hiasa, Akinori Higaki, Osamu Yamaguchi
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	American Heart Journal Plus
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666602224000260

Similar Items

Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis
by: Yang He, et al.
Published: (2019-10-01)

Is There Any Cardiovascular Concern Regarding the Use of Aromatase Inhibitors in Breast Cancer?
by: Tatiana F. G. Galvão

AROMATASE INHIBITORS IN BREAST CANCER THERAPY
by: Hande Karahan, et al.
Published: (2011-04-01)

Aromatase inhibitor strategies in metastatic breast cancer
by: Heather L McArthur, et al.
Published: (2009-07-01)

Clinical utilities of aromatase inhibitors in breast cancer
by: Chumsri S
Published: (2015-05-01)

Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
by: Toru Higuchi, et al.
Published: (2016-01-01)

Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages
by: Luca Gelsomino, et al.
Published: (2020-04-01)

Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis
by: Jeong-Ju Yoo, et al.
Published: (2023-02-01)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
by: Swaathi Jayaraman, et al.
Published: (2020-05-01)

Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer
by: Muriel Lainé, et al.
Published: (2024-06-01)

Network-guided prediction of aromatase inhibitor response in breast cancer.
by: Matthew Ruffalo, et al.
Published: (2019-02-01)

Bone health history in breast cancer patients on aromatase inhibitors.
by: Marilyn L Kwan, et al.
Published: (2014-01-01)

Long-term safety of aromatase inhibitors in the treatment of breast cancer
by: Jean-Marc A Nabholtz
Published: (2008-03-01)

Sweet’s Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer
by: Debora Cardoso, et al.
Published: (2020-02-01)

Potential role of aromatase inhibitors in the treatment of endometriosis
by: Abu Hashim H
Published: (2014-07-01)

Plasma Aromatase Activity Index, Gonadotropins and Estrone Are Associated with Frailty Syndrome in Post-Menopausal Women with Breast Cancer
by: Javier García-Sánchez, et al.
Published: (2022-03-01)

Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
by: Jingxuan Wang, et al.
Published: (2013-01-01)

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.
by: Jingxuan Wang, et al.
Published: (2015-01-01)

A Case of Erythrocytosis in a Patient Treated with an Aromatase Inhibitor for Breast Cancer
by: Abhinav Iyengar, et al.
Published: (2013-01-01)

Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time
by: Adnan Shaaban, et al.
Published: (2024-05-01)

Oxylipins as Biomarkers for Aromatase Inhibitor-Induced Arthralgia (AIA) in Breast Cancer Patients
by: Jessica A. Martinez, et al.
Published: (2023-03-01)

Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review
by: George Zarkavelis, et al.
Published: (2016-09-01)

What influences aromatase inhibitor continuation intention among breast cancer survivors?
by: Young Kyung Seo, et al.
Published: (2021-03-01)

Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
by: Schneider RE, et al.
Published: (2011-10-01)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
by: Junmei Cairns, et al.
Published: (2020-08-01)

Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors
by: Ekaterina Nevedomskaya, et al.
Published: (2014-12-01)

Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors
by: Javier García-Sánchez, et al.
Published: (2022-07-01)

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
by: Generali, D, et al.
Published: (2009)

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
by: Dowsett, M, et al.
Published: (2009)

Virtual Screening of Apigenin and Luteolin as Natural Aromatase Inhibitors for the Treatment of Breast Cancer Patients
by: Baydaa Hamad Obaid Saleh
Published: (2024-10-01)

Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer
by: Sri Lakshmi Hyndavi Yeruva, et al.
Published: (2015-01-01)

Triazoles Synthesis & Applications as Nonsteroidal Aromatase Inhibitors for Hormone-Dependent Breast Cancer Treatment
by: Huda R. M. Rashdan, et al.
Published: (2022-01-01)

Vaginal microbiomes of breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms
by: Pimpun Prasanchit, et al.
Published: (2024-03-01)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
by: Igor Makhlin, et al.
Published: (2022-11-01)

Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer
by: Elona Juozaitytė, et al.
Published: (2014-01-01)

Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer
by: Li Huifang, et al.
Published: (2022-12-01)

Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
by: Bauer M, et al.
Published: (2012-06-01)

Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
by: Frederico Arthur Pereira Nunes, et al.
Published: (2021-07-01)

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors
by: Sally A.D. Romero, et al.
Published: (2020-02-01)

Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
by: Stefano Gonnelli, et al.
Published: (2008-12-01)